“Personalized” battle against GI cancers: ASCO GI 2024 highlights
Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront. While immunotherapy has made a transformational impact in many areas, it hasn’t seen the same success in GI cancers. This has led to rising recognition of cancer heterogeneity and highlighting the need for personalization for therapeutic benefit in subpopulations.
The key highlights at ASCO GI 2024 resonated with the theme of ‘Taking Personalized Care to the Next Level’ and provided a glimpse into the future of personalized medicine for GI cancers. Discover the post-conference takeaways from Inizio Advisory here.
Here’s how we help to shape the future of oncology treatments.
Jump to a slide with the slide dots.
AI in pharma commercialization: Insights you need to know
Discover how AI is revolutionizing pharma commercialization in 2025. Learn how Inizio helps life sciences teams scale AI for real-world performance.
Read moreTop Medical Affairs trends 2025: AI, health equity, and innovation from MAPS Americas
This year’s MAPS Americas Congress brought together the brightest in Medical Affairs - the message was clear: innovation is no longer a differentiator
Read moreHow AI is revolutionizing pharma: 5 key insights from Reuters USA 2025
Explore 5 key AI insights from Reuters Pharma USA 2025—learn how life sciences leaders are using AI to drive humanized engagement, action...
Read more